{"entity":{"id":"outpace-bio","kind":"company","name":"Outpace Bio","aka":[],"tldr":"Outpace Bio uses computer-aided protein design to build engineered T-cell therapies for solid tumours. It is testing two such therapies in women with ovarian and endometrial cancer that has come back.","summary":"Outpace Bio, Inc. is a Seattle company spun out of Lyell Immunopharma in 2021, according to the company, by protein-design and cell-engineering scientists. It uses AI-powered protein design to add modules to engineered T cells: OUTSPACER optimised CARs, OUTSMART designed cytokines, OUTLAST persistence, OUTMATCH paired TCR chains, OUTSAFE (an EGFR-based safety switch responsive to cetuximab) and OUTDRIVE in vivo delivery. OPB-101 is an autologous mesothelin CAR-T with antigen-dependent expression of an OUTSMART designed IL-2. OPB-201 is an autologous PRAME-specific TCR-T carrying a designed potency-enhancing protein. The company announced a $144 million oversubscribed Series B in August 2024. Its first registered cancer trial, NCT07030907, a phase 1a/b study of OPB-101 in platinum-resistant ovarian cancer, was posted on ClinicalTrials.gov in June 2025 and has since been terminated, with the registry giving a business decision as the reason. NCT07664735, a phase 1a/b study of OPB-201 in recurrent endometrial and platinum-resistant ovarian cancer, was posted in June 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://outpacebio.com/"},{"label":"ClinicalTrials.gov: phase 1a/b trial of OPB-101 in platinum-resistant ovarian cancer (NCT07030907)","url":"https://clinicaltrials.gov/study/NCT07030907"},{"label":"ClinicalTrials.gov: phase 1a/b trial of OPB-201 in endometrial and ovarian cancer (NCT07664735)","url":"https://clinicaltrials.gov/study/NCT07664735"},{"label":"Company news page","url":"https://outpacebio.com/news"}],"tags":[],"related":[],"cancers":["ovarian","endometrial"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t","tcr-t","armored-car"],"targets":["mesothelin","prame"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year 2021 is from the company's own 'Our Story' timeline ('Outpace is born'), read on 29 October 2026.","The OPB-101 trial NCT07030907 is listed as terminated on ClinicalTrials.gov; why stopped: business decision.","Series B investors not recorded here; the company news page lists the release headline but the original press release text was not read."],"hq":"Seattle, WA","country":"US","companyType":"cell-therapy","website":"https://outpacebio.com/","founded":2021,"stage":"growth","investors":[],"funding":[{"round":"Series B","year":2024,"amountUsd":144000000,"source":"https://outpacebio.com/news","note":"Oversubscribed Series B announced 1 August 2024, listed on the company news page."}]},"route":"/companies/outpace-bio/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"target":[{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/"},{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"}]}}